{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:54:54Z","timestamp":1790834094417,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"crossref","award":["NV19-05-00410"],"award-info":[{"award-number":["NV19-05-00410"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent studies have underscored the importance of gamma-delta (\u03b3\u03b4) T cells in mediating potent MHC-unrestricted cytotoxicity in numerous malignancies. Here, we analyzed V\u03b41 and V\u03b42 \u03b3\u03b4 T cell subsets in newly diagnosed chronic myeloid leukemia (CML) patients (<jats:italic>n<\/jats:italic>\u2009=\u200940) who had initiated tyrosine kinase inhibitor (TKI) therapy including imatinib (<jats:italic>n<\/jats:italic>\u2009=\u200922), nilotinib (<jats:italic>n<\/jats:italic>\u2009=\u200914) and dasatinib (<jats:italic>n<\/jats:italic>\u2009=\u20094). Patient peripheral blood samples were analyzed at diagnosis and monitored prospectively at 3, 6, 12 and 18\u00a0months post-TKI. \u03b3\u03b4 T cells isolated from healthy donors and CML patients were used against K562, LAMA-84 and KYO-1 cell lines and against primary CML cells in cytotoxicity assays. We found large expansions of V\u03b41 and V\u03b42 T cells in patients at diagnosis compared to age-matched healthy donors (<jats:italic>n<\/jats:italic>\u2009=\u200940) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The \u03b3\u03b4 T cell reconstitution in patients on imatinib and also on nilotinib showed significant reductions of V\u03b41 T cell and V\u03b42 T cell absolute counts at 3\u00a0months compared to diagnosis. Importantly, V\u03b41 and V\u03b42 T absolute cell counts remained at normal levels from 3\u00a0months throughout the follow-up. Next, we observed susceptibility to specific lysis of primary CML tumor cells by V\u03b41 T cells from healthy donors. Furthermore, we determined inherent cytotoxic reactivity by autologous patients\u2019 V\u03b41 T lymphocytes against primary CML tumor cells. Finally, the TCR clonality profiles showed in CML patients mostly polyclonal repertoires regardless of the TKI. Our results provide further evidence into \u03b3\u03b4 T cell antileukemia immunity in CML that might be beneficial for long-term disease control and treatment outcome.<\/jats:p>","DOI":"10.1007\/s00262-022-03312-3","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T21:02:56Z","timestamp":1668459776000},"page":"1209-1224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7291-7975","authenticated-orcid":false,"given":"Andrea","family":"Knight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Piskacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Jurajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirina","family":"Prochazkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"Racil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-8148","authenticated-orcid":false,"given":"Daniela","family":"Zackova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"3312_CR1","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343\u20133356","journal-title":"Blood"},{"key":"3312_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243:290\u2013293. https:\/\/doi.org\/10.1038\/243290a0","journal-title":"Nature"},{"key":"3312_CR3","unstructured":"EMA (2018) Imatinib medac. In: European medicines agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imatinib-medac. Accessed 21 Aug 2022"},{"key":"3312_CR4","unstructured":"EMA (2018) Sprycel. In: European medicines agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sprycel. Accessed 21 Aug 2022"},{"key":"3312_CR5","unstructured":"EMA (2018) Tasigna. In: European medicines agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tasigna. Accessed 21 Aug 2022"},{"key":"3312_CR6","unstructured":"EMA (2018) Bosulif. In: European medicines agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bosulif. Accessed 21 Aug 2022"},{"key":"3312_CR7","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417. https:\/\/doi.org\/10.1056\/NEJMoa062867","journal-title":"N Engl J Med"},{"key":"3312_CR8","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu S, McDonald T, Lin A et al (2011) Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118:5565\u20135572. https:\/\/doi.org\/10.1182\/blood-2010-12-327437","journal-title":"Blood"},{"key":"3312_CR9","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"J-C Chomel","year":"2011","unstructured":"Chomel J-C, Bonnet M-L, Sorel N et al (2011) Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 118:3657\u20133660. https:\/\/doi.org\/10.1182\/blood-2011-02-335497","journal-title":"Blood"},{"key":"3312_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58\u201360. https:\/\/doi.org\/10.1182\/blood-2006-03-011239","journal-title":"Blood"},{"key":"3312_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1146\/annurev.immunol.18.1.975","volume":"18","author":"AC Hayday","year":"2000","unstructured":"Hayday AC (2000) [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18:975\u20131026. https:\/\/doi.org\/10.1146\/annurev.immunol.18.1.975","journal-title":"Annu Rev Immunol"},{"key":"3312_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","volume":"13","author":"P Vantourout","year":"2013","unstructured":"Vantourout P, Hayday A (2013) Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology. Nat Rev Immunol 13:88\u2013100. https:\/\/doi.org\/10.1038\/nri3384","journal-title":"Nat Rev Immunol"},{"key":"3312_CR13","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood-2010-01-255166","volume":"116","author":"A Knight","year":"2010","unstructured":"Knight A, Madrigal AJ, Grace S et al (2010) The role of V\u03b42-negative \u03b3\u03b4 T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 116:2164\u20132172. https:\/\/doi.org\/10.1182\/blood-2010-01-255166","journal-title":"Blood"},{"key":"3312_CR14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1182\/blood-2006-06-028985","volume":"109","author":"S Catellani","year":"2007","unstructured":"Catellani S, Poggi A, Bruzzone A et al (2007) Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood 109:2078\u20132085. https:\/\/doi.org\/10.1182\/blood-2006-06-028985","journal-title":"Blood"},{"key":"3312_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/10428190500051893","volume":"46","author":"V Kunzmann","year":"2005","unstructured":"Kunzmann V, Wilhelm M (2005) Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma 46:671\u2013680. https:\/\/doi.org\/10.1080\/10428190500051893","journal-title":"Leuk Lymphoma"},{"key":"3312_CR16","doi-asserted-by":"publisher","first-page":"e1047580","DOI":"10.1080\/2162402X.2015.1047580","volume":"4","author":"B Castella","year":"2015","unstructured":"Castella B, Foglietta M, Sciancalepore P et al (2015) Anergic bone marrow V\u03b39V\u03b42 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. Oncoimmunology 4:e1047580. https:\/\/doi.org\/10.1080\/2162402X.2015.1047580","journal-title":"Oncoimmunology"},{"key":"3312_CR17","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1182\/blood-2012-03-417519","volume":"120","author":"M Coscia","year":"2012","unstructured":"Coscia M, Vitale C, Peola S et al (2012) Dysfunctional V\u03b39V\u03b42 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood 120:3271\u20133279. https:\/\/doi.org\/10.1182\/blood-2012-03-417519","journal-title":"Blood"},{"key":"3312_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1089\/scd.1.1996.5.503","volume":"5","author":"LS Lamb","year":"1996","unstructured":"Lamb LS, Henslee-Downey PJ, Parrish RS et al (1996) Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother 5:503\u2013509. https:\/\/doi.org\/10.1089\/scd.1.1996.5.503","journal-title":"J Hematother"},{"key":"3312_CR19","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s00262-005-0094-6","volume":"55","author":"PF Meeh","year":"2006","unstructured":"Meeh PF, King M, O\u2019Brien RL et al (2006) Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother 55:1072\u20131080. https:\/\/doi.org\/10.1007\/s00262-005-0094-6","journal-title":"Cancer Immunol Immunother"},{"key":"3312_CR20","doi-asserted-by":"publisher","first-page":"9172","DOI":"10.1158\/0008-5472.CAN-04-2417","volume":"64","author":"A Poggi","year":"2004","unstructured":"Poggi A, Venturino C, Catellani S et al (2004) Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 64:9172\u20139179. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-2417","journal-title":"Cancer Res"},{"key":"3312_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/0032472031000141295","volume":"1","author":"LS Lamb","year":"1999","unstructured":"Lamb LS, Gee AP, Hazlett LJ et al (1999) Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy 1:7\u201319. https:\/\/doi.org\/10.1080\/0032472031000141295","journal-title":"Cytotherapy"},{"key":"3312_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","volume":"39","author":"KT Godder","year":"2007","unstructured":"Godder KT, Henslee-Downey PJ, Mehta J et al (2007) Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 39:751\u2013757. https:\/\/doi.org\/10.1038\/sj.bmt.1705650","journal-title":"Bone Marrow Transplant"},{"key":"3312_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","volume":"85","author":"P Rohon","year":"2010","unstructured":"Rohon P, Porkka K, Mustjoki S (2010) Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 85:387\u2013398. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01501.x","journal-title":"Eur J Haematol"},{"key":"3312_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Auvinen K, Kreutzman A et al (2013) Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27:914\u2013924. https:\/\/doi.org\/10.1038\/leu.2012.348","journal-title":"Leukemia"},{"key":"3312_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/leu.2013.221","volume":"28","author":"KN Wu","year":"2014","unstructured":"Wu KN, Wang YJ, He Y et al (2014) Dasatinib promotes the potential of proliferation and antitumor responses of human \u03b3\u03b4T cells in a long-term induction ex vivo environment. Leukemia 28:206\u2013210. https:\/\/doi.org\/10.1038\/leu.2013.221","journal-title":"Leukemia"},{"key":"3312_CR26","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V et al (2010) Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116:772\u2013782. https:\/\/doi.org\/10.1182\/blood-2009-12-256800","journal-title":"Blood"},{"key":"3312_CR27","doi-asserted-by":"publisher","first-page":"e23022","DOI":"10.1371\/journal.pone.0023022","volume":"6","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Rohon P, Faber E et al (2011) Chronic myeloid leukemia patients in prolonged remission following interferon-\u03b1 monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS ONE 6:e23022. https:\/\/doi.org\/10.1371\/journal.pone.0023022","journal-title":"PLoS ONE"},{"key":"3312_CR28","doi-asserted-by":"publisher","first-page":"e16700","DOI":"10.1371\/journal.pone.0016700","volume":"6","author":"GM Siegers","year":"2011","unstructured":"Siegers GM, Felizardo TC, Mathieson AM et al (2011) Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ Leukemia model. PLoS One 6:e16700. https:\/\/doi.org\/10.1371\/journal.pone.0016700","journal-title":"PLoS One"},{"key":"3312_CR29","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.4049\/jimmunol.0903454","volume":"184","author":"M D\u2019Asaro","year":"2010","unstructured":"D\u2019Asaro M, La Mendola C, Di Liberto D et al (2010) V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 184:3260\u20133268. https:\/\/doi.org\/10.4049\/jimmunol.0903454","journal-title":"J Immunol"},{"key":"3312_CR30","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/14653249.2012.700766","volume":"14","author":"A Knight","year":"2012","unstructured":"Knight A, Mackinnon S, Lowdell MW (2012) Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 14:1110\u20131118. https:\/\/doi.org\/10.3109\/14653249.2012.700766","journal-title":"Cytotherapy"},{"key":"3312_CR31","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H (2022) Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol 97:1236\u20131256. https:\/\/doi.org\/10.1002\/ajh.26642","journal-title":"Am J Hematol"},{"key":"3312_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18302","author":"P Harrington","year":"2022","unstructured":"Harrington P, Dillon R, Radia D et al (2022) Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.18302","journal-title":"Br J Haematol"},{"key":"3312_CR33","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL et al (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21:938\u2013945. https:\/\/doi.org\/10.1038\/nm.3909","journal-title":"Nat Med"},{"key":"3312_CR34","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.4049\/jimmunol.1103710","volume":"188","author":"J Gertner-Dardenne","year":"2012","unstructured":"Gertner-Dardenne J, Castellano R, Mamessier E et al (2012) Human V\u03b39V\u03b42 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol 188:4701\u20134708. https:\/\/doi.org\/10.4049\/jimmunol.1103710","journal-title":"J Immunol"},{"key":"3312_CR35","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035. https:\/\/doi.org\/10.1016\/S1470-2045(10)70233-3","journal-title":"Lancet Oncol"},{"key":"3312_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424\u2013430. https:\/\/doi.org\/10.1200\/JCO.2012.48.5797","journal-title":"J Clin Oncol"},{"key":"3312_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","volume":"77","author":"L Campiotti","year":"2017","unstructured":"Campiotti L, Suter MB, Guasti L et al (2017) Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer 77:48\u201356. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.028","journal-title":"Eur J Cancer"},{"key":"3312_CR38","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757. https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X","journal-title":"Lancet Oncol"},{"key":"3312_CR39","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Str\u00f6mberg U, Schlums H et al (2017) Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31:1108\u20131116. https:\/\/doi.org\/10.1038\/leu.2016.360","journal-title":"Leukemia"},{"key":"3312_CR40","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","volume":"102","author":"D Rea","year":"2017","unstructured":"Rea D, Henry G, Khaznadar Z et al (2017) Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica 102:1368\u20131377. https:\/\/doi.org\/10.3324\/haematol.2017.165001","journal-title":"Haematologica"},{"key":"3312_CR41","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2014.00636","volume":"5","author":"DC Deniger","year":"2014","unstructured":"Deniger DC, Moyes JS, Cooper LJN (2014) Clinical applications of gamma delta T cells with multivalent immunity. Front Immunol 5:636. https:\/\/doi.org\/10.3389\/fimmu.2014.00636","journal-title":"Front Immunol"},{"key":"3312_CR42","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14712598.2019.1634050","volume":"19","author":"E Lo Presti","year":"2019","unstructured":"Lo Presti E, Corsale AM, Dieli F, Meraviglia S (2019) \u03b3\u03b4 cell-based immunotherapy for cancer. Expert Opin Biol Ther 19:887\u2013895. https:\/\/doi.org\/10.1080\/14712598.2019.1634050","journal-title":"Expert Opin Biol Ther"},{"key":"3312_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/leu.2008.273","volume":"23","author":"AJ Barrett","year":"2009","unstructured":"Barrett AJ, Savani BN (2009) Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia 23:53\u201358. https:\/\/doi.org\/10.1038\/leu.2008.273","journal-title":"Leukemia"},{"key":"3312_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen Z, Prinz I, D\u00e9chanet-Merville J et al (2020) Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov 19:169\u2013184. https:\/\/doi.org\/10.1038\/s41573-019-0038-z","journal-title":"Nat Rev Drug Discov"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03312-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T15:11:13Z","timestamp":1681744273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03312-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["3312"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03312-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"6 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local institutional review board of ethics committee of Faculty of Medicine, Masaryk University (#CCF09012015). Patients gave their written informed consents. The study was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}}]}}